Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02687581 · ClinicalTrials.gov registry record · NA
Efficacy of Intermittent Occlusion Therapy Glasses for Amblyopia
A NA study, sponsored by Salus University.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT02687581 is a NA study that was terminated before completion, run by Salus University. The registered enrollment target is 18 participants.
The verdict
NCT02687581, a NA study, was terminated before completion, sponsored by Salus University.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is designed to evaluate the effectiveness of a novel amblyopia treatment - Intermittent occlusion therapy (IO-therapy) glasses (AmblyzTM) in treating severe amblyopia. Children ages 3 to 8 years with severe amblyopia (visual acuity of 20/100 to 20/400 in the amblyopic eye) will be enrolled and randomized into two groups: 1) standard 6-hour patching group or 2) 12-hour IO-therapy glasses group. The study also observe the effectiveness of IO-therapy glasses on two types of difficult amblyopia: deprivation amblyopia associated with congenital or developmental cataract, and myopic anisometropic amblyopia.
Interventions
- DEVICE IO-therapy Glasses
- DEVICE patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-12-19 |
| Est. Completion | 2021-05-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02687581
The ClinicalTrials.gov registry entry for NCT02687581 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Salus University, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IO-therapy Glasses is the first listed.
NCT02687581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02687581 about?
NCT02687581 is a clinical study titled "Efficacy of Intermittent Occlusion Therapy Glasses for Amblyopia". This study is designed to evaluate the effectiveness of a novel amblyopia treatment - Intermittent occlusion therapy (IO-therapy) glasses (AmblyzTM) in treating severe amblyopia. Children ages 3 to 8 years with severe amblyopia (visual acuity of 20/100 to 20/400 in the amblyopic eye) will be enroll...
What is the current status of trial NCT02687581?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2016-12-19. Estimated completion is 2021-05-30.
What interventions are being tested in trial NCT02687581?
The interventions under investigation include: IO-therapy Glasses (DEVICE), patch (DEVICE).
Who is sponsoring clinical trial NCT02687581?
This trial is sponsored by Salus University, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.